Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials

BACKGROUND: Due to the short half-life of levodopa, immediate-release carbidopa-levodopa (IR CD-LD) produces fluctuating LD concentrations, contributing to a risk of eventual motor complications. IPX066 was designed to rapidly attain therapeutic LD concentrations and maintain them to allow a dosing...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Parkinsons Dis
Главные авторы: Nausieda, Paul A., Hsu, Ann, Elmer, Lawrence, Gil, Ramon A., Spiegel, Joerg, Singer, Carlos, Khanna, Sarita, Rubens, Robert, Kell, Sherron, Modi, Nishit B., Gupta, Suneel
Формат: Artigo
Язык:Inglês
Опубликовано: IOS Press 2015
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927929/
https://ncbi.nlm.nih.gov/pubmed/26444090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-150622
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы